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27.1 Introduction.   
It is a condition of use of many drugs that extra care and attention should be used when 
administered to pregnant women. It is well established that some drugs can have temporary 
or permanent effects on the developing foetus. Drugs that have such an effect are known as 
teratogens, the most notorious being thalidomide which was prescribed to pregnant women 
as a treatment for morning sickness and resulted in a variety of serious birth defects for many 
thousands of babies. However, this chapter is concerned with drugs that are used to treat 
medical complaints arising from problems occurring in pregnancy and labour and not with 
adverse effects on mother or foetus as a result of drug administration. 
27.2 Common complaints in pregnancy and labour and their treatments 
27.2.1 Pre-eclampsia and eclampsia.  
Pre-eclampsia is defined as a hypertensive state of unknown cause occurring in pregnancy. 
Pre-eclampsia is diagnosed when consistent systolic pressures over 140mm Hg and/or 
diastolic pressures over 90 mm Hg are observed. These changes are accompanied by elevated 
protein levels in the urine (hyperproteinuria). Pre-eclampsia can progress to eclampsia, a 
condition characterised by tonic clonic convulsive seizures. Treatment involves reduction of 
blood pressure with antihypertensives and control of seizures with anticonvulsives. If these 
treatments are unsuccessful, abortion or delivery of the foetus is the only effective alternative.  
Most antihypertensives exert their effects by dilating blood vessels, easing constricted blood 
flow and reducing intravessel pressure. These drugs are used to treat a number of disease 
states including angina, congestive heart failure and acute myocardial infarction in which 
lowering of blood pressure is crucial in alleviating symptoms. Antihypertensives used in the 
treatment of pre-eclampsia include nifedipine, hydralazine, labetalol and methyldopa.  
Nifedipine is a selective blocker of L-type voltage-sensitive calcium channels in arterial 
smooth muscle. Inhibition of these channels results in reduced calcium entry into these cells 
causing vasodilation. Adverse effects of nifedipine include headache, flushing, nausea, 
vomiting and peripheral oedema.  
A second antihypertensive used in the treatment of pre-eclampsia is hydralazine. Although 
its exact mechanism of action is unclear, hydralazine degrades to nitric oxide which is a 
direct acting vasodilator. Hydralazine has similar adverse effects to nifedipine.  
Labetalol is a mixed  adrenoceptor antagonist () which produces peripheral 
vasodilation by blocking the effects of sympathetic nervous system thereby reducing blood 
pressure. Labetalol has a number of adverse effects including postural hypotension and 
bronchoconstriction and as such should not be used in patients with asthma, bradycardia and 
second or third degree atrioventricular block.  
Methyldopa is converted to its active metabolite -methylnoradrenaline in sympathetic 
neurons and stored in the secretory vesicles of these cells. When released, α-
methylnoradrenaline acts as an agonist of presynaptic central nervous system α2-adrenergic 
receptors. Activation of these receptors in the brainstem appears to inhibit sympathetic 
nervous system output and lower blood pressure. However, it is contraindicated in patients 
with active liver disease and phaeochromocytoma (tumour of the adrenal gland) and use of 
methyldopa may exacerbate depression in sufferers. Adverse effects are those associated 
with sympathetic disruption and include sedation, orthostatic hypotension, dry mouth and 
rash. 
Progression of pre-eclampsia to eclampsia is characterised by the appearance of tonic clonic 
seizures. Magnesium sulphate is the drug of choice to prevent these convulsions.  The 
resultant elevated blood magnesium levels (hypermagnesaemia) depresses neuronal activity, 
reducing excitation and calming the uncontrolled nerve firing that can result in seizures. The 
magnesium competes with excitatory calcium decreasing neurotransmitter release at the 
synapse. This treatment is contraindicated with patients with existing elevated blood 
magnesium levels and those with kidney problems. Concomitant use of magnesium sulphate 
and nifedipine can result in hypotension and use of these drugs in combination should be 
monitored. Adverse effects include myasthenia gravis, muscle weakness, respiratory 
depression, bradycardia and thirst. 
When pharmacological treatment for pre-eclampsia and eclampsia fails, there is real concern 
for the safety of the mother. Abortion or delivery by caesarean section or labour induction is 
the treatment of choice. Myometrial stimulants (also known as oxytocics) are used for 
induction and augmentation of labour, prevention and treatment of post-partum haemorrhage, 
control of bleeding due to incomplete abortion, active management of the third stage of 
labour. The oxytocics most commonly used are oxytocin, prostaglandin E and ergometrine.  
Oxytocin is a 9 amino acid produced in the posterior pituitary gland. Exogenous oxytocin, 
administered by means of continuous infusion by pump, stimulates the frequency and force of 
uterine contractions, initiating labour and parturition. Prolonged use can result in water 
intoxication, uterine rupture and hypotension in the mother and bradycardia, brain damage, 
seizures and death in the infant.  
Prostaglandin E2 (dinoprostone) and prostaglandin E1 (misoprostol) are first line drugs 
of choice as labour inductor. These form part of the eicosanoids, a family of lipid derived 
hormones which have a multiplicity of different cellular functions including smooth muscle 
contraction.  
Finally, ergometrine, an alkaloid structurally similar to LSD can also be used to facilitate 
delivery of the placenta and to prevent bleeding after childbirth by reducing blood flow 
through constriction of smooth muscle in the blood vessel walls causing vessel narrowing. It 
is usually combined with oxytocin as syntometrine. 
27.2.2 Suppression of early labour.  
A number of drugs are used as uterine relaxants. These drugs, known as tocolytics, are 
particularly useful in the suppression of early or premature labour affording time for further 
foetal development and prolonging foetal survival. Several drug classes have been shown to 
possess tocolytic properties. These include 2 adrenergic receptor agonists, oxytocin 
antagonists and calcium channel blockers.   
Included in the 2 adrenoceptor agonist class are terbutaline, ritodrine, salbutamol, 
fenoterol and adrenaline. These drugs work by directly activating adrenergic receptors that 
mediate smooth muscle relaxation terminating uterine contractions. However, these drugs can 
have a number of adverse effects on both the mother and the foetus due to their ability to act 
on the respiratory and cardiovascular systems. Common maternal adverse effects include 
cardiac arrhythmias, altered thyroid function and tachycardia whilst tachycardia, 
hypoglycaemia, hypotension and myocardial ischaemia have been noted in the foetus and 
neonate.  
Atosiban is a peptide analogue of oxytocin which antagonises the uterine contracting 
properties of the hormone at its receptor resulting in cessation of preterm labour. It is 
preferred over the 2 adrenergic agonists due to its lower incidence of adverse effects 
although reactions to the drug such as nausea, vomiting and hyperglycaemia have been noted.  
Calcium channel blockers such as nifedipine, which has previously been discussed for its use 
as an antihypertensive in pre-eclampsia is also has tocolytic properties.   
27.2.3 Neonatal respiratory distress syndrome.  
One consequence of premature birth is impairment of lung development in the neonate. This 
manifests itself as neonatal respiratory distress syndrome and is characterised by a deficiency 
in lung surfactant which causes the integrity of the lung structure to collapse resulting in 
severe breathing difficulties. Intraventricular haemorrhage and death may follow. 
Corticosteroids such as dexamethasone and bexamethasone are used in conjunction with 
tocolytics as therapies to treat this syndrome. The tocolytics prevent premature birth giving 
the lungs extra time to develop whilst the steroids act via cell surface receptors to directly 
activate survival genes. Adverse reactions to these steroids include fluid and electrolyte 
imbalances, muscle weakness, GI disturbances and hypertension. 
27.2.4 Postpartum haemorrhage.  
Postpartum haemorrhage is the leading cause of maternal mortality causing approximately 
140000 deaths each year.  Oxytocics, particularly oxytocin, are the preferred treatment. 
Problems associated with the use of oxytocin are outlined above.  
27.2.5 Prolactin excess.  
Prolactin is a peptide hormone secreted by lactotrophic cells in the anterior pituitary. 
Increases in prolactin secretion, during pregnancy, results in maturation of milk secreting 
duct in the mammary gland. Although not restricted to pregnant women, excess production of 
prolactin (hyperprolactinaemia) will result in overactive, secreting mammary tissue. 
Prolactin secretion is under the control of D2 dopamine receptors in the lactotrophic cells.  
Dopamine, secreted from the hypothalamus, acts on these receptors to inhibit the prolactin 
production. Hyperprolactinaemia results when circulating levels of dopamine drop and the 
inhibitory processes compromised resulting in large levels of circulating prolactin in the 
blood. Treatment is with bromocriptine, a dopamine receptor agonist, which decreases 
excessive prolactin secretion. Adverse effects include nausea and vomiting, dizziness and 
constipation. 
27.2.6 Nausea.  
Nausea and vomiting during pregnancy (also known as morning sickness) is common during 
the early stages of pregnancy. These are multiple causes ranging from changes in circulating 
steroid hormones such as oestrogen and progesterone to hypoglycaemia resulting from 
placental transfer of glucose from the mother to the foetus. In most cases no treatment is 
required as the condition will normally disappear after the first trimester of pregnancy. 
However, severe morning sickness known as hyperemesis gravidarum (HG) affecting around 
one in 1,000 pregnant women can occur. The symptoms of hyperemesis gravidarum include 
repeated vomiting, weight loss and dehydration. Treatment usually involves hospitalisation, 
and the administering of intravenous liquids and nutrition. The possible complications 
associated with untreated hyperemesis gravidarum include electrolyte imbalances, extreme 
depression and anxiety and malnourishment of the foetus.   
In extreme cases of morning sickness, antiemetics may be prescribed. These drugs work by 
blocking neurotransmitter inputs to the chemoreceptor trigger zone (CTZ), the principal 
vomiting control centre, of the medulla. First choice is ondansetron, a blocker of 5HT-3 
receptors found in the CTZ, given orally or by injection. This drug, which is also used as an 
antiemetic during cancer chemotherapy, has a number of unwanted effects such as headache 
and GI upset. Other drugs used include promethazine (histamine H1 receptor blocker) and 
metoclopramide and chlorpromazine (dopamine D2 receptor blockers).  
 
